Late Effects after Pediatric HSCT: State of the Science, Future Directions

描述（由申请人提供）：随着造血细胞移植（HCT）在过去二十年中频率，安全性和有效性的提高，长期幸存者的数量显着增加。接受这种高强度治疗方式的儿童处于许多晚期毒性的高风险中。hct相关的晚期效应是发病率和更重要的死亡率的重要原因。移植时年龄小于18岁的HCT幸存者面临的晚期死亡风险是一般人群的17倍。这些非复发相关的晚期死亡大多数可归因于感染、心脏和肺部原因。必须确定HCT幸存者发病和死亡的这些和其他原因的危险因素，以便1)可以对治疗进行适当的修改，2)可以为HCT幸存者制定筛查和/或干预试验和健康维护建议。由于许多这些不良事件的罕见性，有必要跟踪大量队列，以达到有意义的关联。多机构研究可以获得较高的数据，也可以使研究结果具有普遍性，因为它们考虑了不同部位移植实践的可变性。在过去几年中，开展多机构儿科HCT研究的能力显著提高，同时在HCT后期效应研究方面培养了一批熟练的儿科专家。现在有了专业知识和基础设施，使这一领域能够进入高质量的多中心研究，我们为2011年4月在弗吉尼亚州阿灵顿举行的会议寻求资金，旨在确定最佳问题，用最具创新性和信息量的方法接近它们，并就如何优先考虑工作和向前发展达成共识。会议组委会由迟发效应和多中心儿科HCT研究领域的国际专家组成。会议组织者召集了一组杰出的专家，他们同意讨论以下领域：1)HCT后晚期效应研究中的方法挑战，2)HCT后晚期效应的生物标志物和/或遗传易感因素的研究，以及3)HCT后器官系统功能障碍和健康相关生活质量的研究方法。第三项将讨论的具体主题包括HCT后的长期免疫缺陷、肺、胃肠、肝、肾、心血管、神经认知和内分泌功能障碍，以及HCT后的生活质量和功能结局。会议的目标是确定优先事项，建立工作组以推进高优先项目，设定时间表以实现既定目标，并公布会议结论。这次会议将为新一代高质量的多中心晚期效应研究奠定基础，这些研究最终将有助于确定旨在改善接受HCT的儿童长期预后的方法。

DESCRIPTION (provided by applicant): As hematopoietic cell transplantation (HCT) has improved in frequency, safety and efficacy over the last two decades, the number of long-term survivors has markedly increased. Children undergoing this intense therapeutic modality are at high risk of a number of late toxicities. HCT-related late effects are a significant cause of morbidity and more importantly, mortality. HCT survivors who are <18yrs of age at the time of transplant face a risk of late mortality that is 17 fold higher than the general population. The majority of these non-relapse related late deaths can be attributed to infectious, cardiac and pulmonary causes. Risk factors for these and other causes of morbidity and mortality in HCT survivors must be identified so that 1) appropriate modifications in therapy can be made and 2) screening and/or intervention trials and health maintenance recommendations for HCT survivors can be developed. Due to the rarity of many of these adverse events, there is a need to follow large cohorts in order to arrive at meaningful associations. Multi-institutional studies allow one to achieve high numbers and also allow generalizability of findings, because they take into account the variability in the transplant practices at the various sites. In the last few years, significant improvements in the ability to perform multi-institutional pediatric HCT studies have combined with the development of a skilled group of pediatric experts in HCT late effects research. With expertise and infrastructure now available to allow this field to move into high-quality multi-center studies, we seek funding for a conference in Arlington, VA in April of 2011 aimed at defining the best questions, approaching them with the most innovative and informative methodologies, and coming to a consensus about how to prioritize the work and move forward. The conference organizing committee is composed of international experts in the fields of late effects and multicenter pediatric HCT research. Conference organizers have assembled a distinguished group of experts who have agreed to address the following areas: 1) methodological challenges in the study of late effects after HCT, 2) studies of biomarkers and/or genetic predisposition to late effects after HCT, and 3) approaches to the study of organ system dysfunction and health-related quality of life after HCT. Specific topics that will be addressed in item number three above include long-term post-HCT immunodeficiency, pulmonary, gastrointestinal, hepatic, renal, cardiovascular, neurocognitive and endocrine dysfunction, and quality of life and functional outcomes after HCT. The goal of the meeting will be to define priorities, establish working groups to move high-priority projects forward, set timelines to achieve established goals, and publish conference conclusions. This meeting will lay the foundation for a new generation of high-quality multi-center late effects studies that will eventually aid in defining approaches aimed at improving long-term outcomes in children undergoing HCT. PUBLIC HEALTH RELEVANCE: Because bone marrow transplantation occurs rarely in children, large studies that could allow us to better understand the seriousness and frequency of adverse medical complications that can occur several years after the transplant have not occurred. This proposal requests funding to support a conference attended by recognized experts in late complications after pediatric transplant therapy aimed at prioritizing topics, choosing the best approaches, and organizing specific efforts to plan studies. These studies will allow us to define aspects of the transplant procedure associated with increased risk, resulting in appropriate modifications of future transplant approaches and allowing the design of screening or intervention trials and health maintenance recommendations for transplant survivors.